DALIAN, China -- Chinese drugmaker Sinopharm has completed construction of a plant in Wuhan for mass production of a coronavirus vaccine candidate now under development, doubling its capacity to more than 200 million doses a year
The state-backed company, known formally as China National Pharmaceutical Group, will be able to make 100 million doses a year at the site. The investment amount has not been disclosed. After the groundbreaking in March, construction took place quickly with support from the local government.
